长春瑞滨联合奥沙利铂用于中期非小细胞肺癌术后辅助化疗近期疗效分析  

An Analysis of Short-term Outcomes of Postoperative Chemotherapy by Vinorelbine Combined with Oxaliplatin in Patients with StageⅡ-Ⅲa Non-small Cell Lung Cancer

作　　者：胡思远[1] 杨世疆[1] 薛亚军[1] 朱志军[1] 侯量[1] 罗波[1] 魏育涛[1] 朱佳龙[1] 

机构地区：[1]新疆石河子大学医学院第一附属医院心胸外科,石河子832008

出　　处：《中国医药导刊》2010年第11期1944-1945,共2页Chinese Journal of Medicinal Guide

摘　　要：目的:评价长春瑞滨联合奥沙利铂用于中期非小细胞肺癌术后辅助化疗近期临床疗效和毒性反应。方法:54例Ⅱ～Ⅲ期NSCLC患用长春瑞滨联合奥沙利铂治疗后评价疗效。结果:54例患者均可评价,获得CR30例,PR17例,有效率87.1%(47/54),近期化疗疗效和临床分期、病理类型无关(P>0.05)。最主要的毒副反应为白细胞降低及胃肠道反应,但均可耐受。结论:长春瑞滨联合奥沙利铂用于中期非小细胞肺癌术后辅助化疗近期疗效显著,毒性反应可以耐受,可以成为首选方案。Objective： To observe the clinical effect and side effects of postoperative chemotherapy by Vinorelbine （NVB） Combined with Oxaliplatin（OXA） in patients with stage Ⅱ-Ⅲa Non-small cell lung cancer（NSCLC）.Methods：54 patients with stage Ⅱ-Ⅲa NSCLC The patients were treated with NVB 25mg/m^2 on the day 1 and day 8,OXA 100mg on the day 1 to 3, delivered by venous injection.The therapy was repeated every 21-28 days more than 2 cycles.Results：In the 54 cases,30 cases CR,17 cases PR,5 cases SD and 2 cases PD. The response rate（CR＋PR） was 87.1%,Tbere was no significant difference between the different stage and pathological types（P〉0.05）.The main side-effects Were marrow suppression and gastrointestinal reactions. Conclusion：The clirtical effective of NVB combined with OXA was high in the treatment of postoperative chemotherapy in patients with stage Ⅱ-Ⅲa NSCLC. And the side effects could be tolerated by the patients. So the treatment method was worth to be promoted in clinical.

关 键 词：非小细胞肺癌 长春瑞滨 奥沙利铂 术后 辅助化疗 

分 类 号：R734.2[医药卫生—肿瘤]